Price (90d)
$162.07Signal Score (90d)
119Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $875.26M | $70.79M | $11.13 |
| 2024 | $479.95M | $52.18M | $10.23 |
| 2023 | $247.65M | $-45.79M | $-10.39 |
| 2022 | $219.29M | $-424.78M | $-100.50 |
| 2021 | $331.53M | $132.59M | $33.55 |
Social Signal Score
Earnings
Tue, Nov 17(in 3 months)
Consensus estimate $5.26 per share
Typical surprise +63.4% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$9.38 vs $4.95beat
- Thu, Apr 30$6.52 vs $3.99beat
- Thu, Mar 5$1.61 vs $5.56miss
- Wed, Nov 19$7.76 vs $1.81beat
- Wed, Oct 22$-2.95 vs $-1.43miss
- Tue, May 13$2.56 vs $3.04miss
Estimates and results for NUTX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Valuation
Project earnings forward and see what return today's price implies.
Seeded from NUTX's reported EPS growth of -24.1% a year over 4 years. Historical EPS growth of -24% would project the company towards zero. Floored at -15% as a starting point.
- EPS in 5 years
- $4.94
- Implied price
- $74.06
- Return from $187.42
- -16.9% a year
To earn 15.0% a year on these assumptions you'd need to buy at $36.82 — -80.4% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 11 | 13 | 15 | 17 | 19 |
|---|---|---|---|---|---|
| -25.0% | -31.1% | -28.8% | -26.7% | -24.9% | -23.2% |
| -20.0% | -26.5% | -24.0% | -21.8% | -19.9% | -18.0% |
| -15.0% | -21.9% | -19.3% | -16.9% | -14.8% | -12.9% |
| -10.0% | -17.4% | -14.5% | -12.1% | -9.8% | -7.8% |
| -5.0% | -12.8% | -9.8% | -7.2% | -4.8% | -2.7% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Mentions (2)
- Newsseekingalpha.com·3d ago·Positive
Nutex Health: A 'Strong Buy' Amid Margin Expansion, Regulatory Tailwinds (Upgrade) Nutex Health upgraded to "Strong Buy" as margin expansion and patient volume growth drive bullish outlook. Despite a 13% YoY revenue decline, Q2 saw 9.6% patient volume growth and significant, sustainable operating cost reductions. CMS administrative fee cuts and the HaloMD contract amendment are expected to lower normalized costs by 25%–30% in future periods.
View source ↗ - Newsseekingalpha.com·7d ago·Positive
Nutex Health Inc. (NUTX) Q2 2026 Earnings Call Transcript Nutex Health Inc. (NUTX) Q2 2026 Earnings Call Transcript
View source ↗